Free Trial

Amgen (AMGN) Stock Forecast & Price Target

Amgen logo
$290.13 -5.30 (-1.79%)
Closing price 10/10/2025 04:00 PM Eastern
Extended Trading
$289.44 -0.69 (-0.24%)
As of 05:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amgen - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
1
Hold
11
Buy
8

Based on 20 Wall Street analysts who have issued ratings for Amgen in the last 12 months, the stock has a consensus rating of "Hold." Out of the 20 analysts, 1 has given a sell rating, 11 have given a hold rating, and 8 have given a buy rating for AMGN.

Consensus Price Target

$309.42
6.65% Upside
According to the 20 analysts' twelve-month price targets for Amgen, the average price target is $309.42. The highest price target for AMGN is $383.00, while the lowest price target for AMGN is $195.00. The average price target represents a forecasted upside of 6.65% from the current price of $290.13.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for AMGN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Amgen and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AMGN Analyst Ratings Over Time

TypeCurrent Forecast
10/13/24 to 10/13/25
1 Month Ago
9/13/24 to 9/13/25
3 Months Ago
7/15/24 to 7/15/25
1 Year Ago
10/14/23 to 10/13/24
Strong Buy
0 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
8 Buy rating(s)
7 Buy rating(s)
8 Buy rating(s)
11 Buy rating(s)
Hold
11 Hold rating(s)
12 Hold rating(s)
12 Hold rating(s)
11 Hold rating(s)
Sell
1 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$309.42$304.43$307.82$326.30
Forecasted Upside6.65% Upside10.14% Upside5.23% Upside-0.62% Downside
Consensus RatingHoldHoldHoldModerate Buy

AMGN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AMGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Amgen Stock vs. The Competition

TypeAmgenMedical CompaniesS&P 500
Consensus Rating Score
2.35
2.33
2.52
Consensus RatingHoldHoldModerate Buy
Predicted Upside6.65% Upside1,022.61% Upside177.78% Upside
News Sentiment Rating
Positive News

See Recent AMGN News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/8/2025Weiss Ratings
0 of 5 stars
 UpgradeHold (C+)Buy (B-)
9/26/2025Bank of America
4 of 5 stars
Tim Anderson
Tim Anderson
Not Rated
Boost TargetUnderperform$261.00 ➝ $272.00+0.05%
9/24/2025Citigroup
3 of 5 stars
Geoff Meacham
Geoff Meacham
Not Rated
Boost TargetNeutral$310.00 ➝ $315.00+9.83%
9/3/2025Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Perform
8/25/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$328.00 ➝ $342.00+18.03%
8/6/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetEqual Weight$330.00 ➝ $333.00+17.09%
8/6/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetNeutral$326.00 ➝ $317.00+11.60%
6/24/2025William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOutperform
6/24/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$305.00+11.95%
5/20/2025Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$288.00+4.29%
5/8/2025Erste Group Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
5/7/2025Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$235.00 ➝ $280.00+3.08%
5/2/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOutperform$324.00 ➝ $320.00+14.33%
3/5/2025Johnson Rice
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Set Target$294.00-10.47%
2/5/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingEqual Weight
1/8/2025Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetHold$333.00 ➝ $298.00+13.71%
1/2/2025Piper Sandler Companies
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOverweight$310.00+18.94%
11/27/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower Target$305.00 ➝ $285.00+1.78%
11/27/2024Redburn Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower Target$200.00 ➝ $195.00-30.36%
11/27/2024Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower Target$349.00 ➝ $302.00+7.85%
11/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoveragePeer Perform
11/12/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy$380.00 ➝ $380.00+28.07%
10/21/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$381.00 ➝ $383.00+20.14%
10/17/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$380.00+18.15%
10/7/2024Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetEqual Weight$300.00 ➝ $315.00-0.48%
9/25/2024Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingUnderperform$215.00 ➝ $215.00-31.92%
9/16/2024Dbs Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/7/2024Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOutperform$380.00 ➝ $380.00+22.53%
6/27/2024Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$300.00 ➝ $340.00+8.87%
5/3/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetOutperform$336.00 ➝ $355.00+12.91%
2/7/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperformMarket Perform
2/7/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$313.00 ➝ $350.00+10.73%
12/21/2023Daiwa Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeNeutralBuy$264.00 ➝ $320.00+16.29%
10/20/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingNeutral$270.00-3.69%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 05:59 AM ET.


Should I Buy Amgen Stock? AMGN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, October 12, 2025. Please send any questions or comments about these Amgen pros and cons to contact@marketbeat.com.

Amgen
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Amgen Inc.:

  • The current stock price is around $315, reflecting a stable valuation in the market.
  • Amgen Inc. reported earnings per share (EPS) of $6.02 for the latest quarter, significantly exceeding analysts' expectations, indicating strong financial performance.
  • The company has a solid revenue growth of 9.4% year-over-year, showcasing its ability to expand and generate more income.
  • Amgen Inc. offers a competitive dividend yield of approximately 3.3%, providing investors with a reliable income stream.
  • The company has received multiple upgrades from analysts, with a consensus rating of "Hold" and a target price of around $309.42, suggesting potential for price appreciation.

Amgen
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Amgen Inc. for these reasons:

  • The payout ratio is currently at 77.84%, which indicates that a significant portion of earnings is being distributed as dividends, potentially limiting funds available for reinvestment in growth.
  • Despite recent upgrades, the stock has a mixed analyst outlook with a notable number of "Hold" ratings, suggesting uncertainty about future performance.
  • Amgen Inc. operates in a highly competitive pharmaceutical market, which can impact its market share and profitability.
  • The company’s net margin of 18.96% may indicate pressure on profitability, which could affect future earnings growth.
  • There is a risk of regulatory changes in the healthcare sector that could adversely affect Amgen Inc.'s operations and profitability.

AMGN Forecast - Frequently Asked Questions

According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Amgen is $309.42, with a high forecast of $383.00 and a low forecast of $195.00.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There is currently 1 sell rating, 11 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.

According to analysts, Amgen's stock has a predicted upside of 6.65% based on their 12-month stock forecasts.

Over the previous 90 days, Amgen's stock had 1 upgrade by analysts.

Amgen has been rated by research analysts at Bank of America, Citigroup, Morgan Stanley, Piper Sandler, Raymond James Financial, UBS Group, and Weiss Ratings in the past 90 days.

Analysts like Amgen more than other "medical" companies. The consensus rating score for Amgen is 2.35 while the average consensus rating score for "medical" companies is 2.33. Learn more on how AMGN compares to other companies.


This page (NASDAQ:AMGN) was last updated on 10/13/2025 by MarketBeat.com Staff
From Our Partners